HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
BIOBOARD - NORTH AMERICA
Impel NeuroPharma completes industry's first nose-to-brain human imaging study
Impel NeuroPharma announced the completion of its human proof of concept study with the Precision Olfactory Delivery (POD) technology demonstrating nose-to-brain delivery using SPECT imaging, a first in the pharmaceutical and biotechnology industries. The successful trial opens the door for central nervous system (CNS) drugs to be delivered directly to the human brain, allowing potential treatments for complex neurological conditions that were previously excluded by the blood-brain barrier (BBB). Imaging showed that the POD device successfully deposited a therapeutic amount of radiolabeled tripeptide into the deep nasal cavity that then enabled rapid and significant delivery to the central nervous system, bypassing the BBB.

“This is a major milestone for the company and groundbreaking for the industry,” says CEO, Michael Hite. “We conclusively demonstrated the POD technology can deliver clinically meaningful levels of biologic drug products to the central nervous system (CNS).”

“Our goal is to advance the treatment of CNS diseases by enabling the delivery of molecules that currently can’t be developed as therapeutics because of the blood-brain barrier. Nose-to-brain delivery offers an opportunity to bypass the BBB, providing hope for a broad range of CNS conditions that currently lack a good treatment option,” Hite added.

Dr. William Frey II, Director of the Alzheimer's Research Center and Professor of Pharmaceutics, Neurology and Neuroscience at the University of Minnesota commented, “Since the discovery in 1989 that intranasal delivery could be used to bypass the blood-brain barrier, there has been a need for a safe, effective and reliable device for targeting the upper third of the nasal cavity. The Impel study is exciting because it confirms that the pathway is conserved across animal species and can be utilized clinically to facilitate delivery of drugs. The study demonstrated that the Impel POD nasal device successfully targets the upper posterior portion of the human nasal cavity resulting in rapid therapeutic delivery to multiple brain regions, including those involved in Alzheimer's, Parkinson's and stroke.”

“We’ve made great progress in preclinical studies, with multiple successful programs with National Institutes of Health (NIH), the Department of Defense, and several pharma collaborators, but we’re really excited to advance the POD technology into the clinic,” John Hoekman, PhD, Impel's Chief Scientific Officer commented. Furthering its mission, Impel will continue to broaden its clinical experience with two IND-approved human studies later this year, including one at the University of Washington.

Impel has also recently received a >$650,000 Small Business Investigational Research (SBIR) grant from the NIH to develop a cost-effective version of the POD device for use in research labs. “The NIH has recognized the potential in nose-to-brain drug delivery. By expanding the application of the POD technology in basic and applied neuroscience we are hoping to accelerate development of therapeutics uniquely enabled by this route,” Hoekman added.

Impel has focused on collecting additional performance and safety data for the POD technology and expanding its capabilities for clinical support of pharmaceutical and biopharma partners. Impel has recently signed research agreements with two additional pharmaceutical partners with programs targeting neurological disorders. To date, Impel has entered into seven research agreements with pharmaceutical and device partners with active CNS pipelines, including four of the ten largest pharmaceutical companies.

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
news Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
news Wheat Genome Sequencing Gets Major Boost
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy